Opinion|Videos|November 22, 2024
Final Thoughts
The panel discussion concludes with final thoughts on the future landscape of newly diagnosed multiple myeloma.
Advertisement
Episodes in this series
Advertisement
Related to this article
ENDURANCE trial finds fixed 2-year lenalidomide maintenance matches continuous therapy for standard-risk multiple myeloma survival, guiding oncology pharmacists on MM regimen toxicity.
Advertisement
Advertisement
Trending on Pharmacy Times
1
PCSK9 Inhibition Lowers LDL-C in Patients With Kidney Disease
2
The Growing Role the Specialty Pharmacy Team Plays in Helping Breast Cancer Patients Navigate Treatment
3
GLP-1 RAs Tied to Lower Kidney Failure Risk in Patients With Obesity, CKD
4
Kidney Week 2026: Pharmacists' Growing Role in Kidney Care
5